University of Washington Launches Vilya with $50 Million to Develop Membrane-Permeable Peptide Drugs

University of Washington researchers developed custom peptides that penetrate cell membranes, enabling a new class of drugs with combined benefits of small molecules and protein therapeutics. They founded Vilya, backed by $50 million from Arch Venture Partners, to commercialize this drug platform described in Cell.

DDavid Baker UUniversity of Washington IInstitute for Protein Design